Up-regulated miR-106b inhibits ox-LDL-induced endothelial cell apoptosis in atherosclerosis

Yunqing Zhang1, Li Wang2, Jie Xu3, Xiaomei Kong3, and Lin Zou1

1Department of Cardiology, Zuanshiwan Branch of The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
2Department III of Cardiology, The Central Hospital of Dalian, Dalian, Liaoning, China
3Department of Endocrinology, Zuanshiwan Branch of The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

Abstract

This research aimed to explore the molecular mechanism of microRNA (miR)-106b in cell apoptosis of atherosclerosis (AS). Human aortic endothelial cells (HAECs) were divided into control group, oxidized-low-density lipoproteins (ox-LDL) group, miR-106b NC + ox-LDL group, miR-106b mimics + ox-LDL group, miR-106b mimics + PTEN + ox-LDL group, and miR-106b mimics + empty + ox-LDL group. Real-time fluorescence quantitative polymerase chain reaction, cholecystokinin, TdT-mediated biotinylated nick end-labeling assay, luciferase reporter gene assay, and flow cytometry analysis were performed to determine the morphology, proliferation, and apoptosis in HSECs. Moreover, the levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), Bcl-2, p-P13K, and p-AKT in HAECs were detected by western blot. MiR-106b was down-regulated in ox-LDL-induced HAECs. PTEN was the target gene of miR-106b-5p. Overexpression of PTEN inhibited the anti-apoptotic effect of miR-106b. Compared with the control group, the proportion and number of HAECs apoptosis and Bax, caspase-3, and caspase-9 expression in ox-LDL and miR-106b mimics + PTEN + ox-LDL groups were significantly increased (all P < 0.05). Moreover, the activity of HAECs and Bcl-2 were decreased significantly (all P < 0.05). Overexpression of miR-106b in ox-LDL-induced AS inhibited endothelial cell apoptosis. Furthermore, miR-106b might activate the PI3K/AKT pathway by down-regulating the expression of PTEN in ox-LDL-induced HAECs.

Key words: Atherosclerosis; ox-LDL; miR-106b; PTEN; P13K/AKT; Endothelial cell apoptosis

Introduction

Atherosclerosis (AS) is a chronic inflammatory process of the arterial wall caused by hyperlipidemia (1). There are two prominent hallmarks of AS pathogenesis including the accumulation of cholesterol in the endothelial lining of arteries carried by low-density lipoproteins (LDL) and chronic inflammation due to a high ratio of prooxidants to antioxidants (2,3). As a systemic disease, AS and its accompanying clinical complications are important factors in long-term mortality and morbidity worldwide (4,5). Although various strategies such as drug therapy and surgery have been used for the clinical treatment of AS, the outcome of AS treatment is still not optimal due to the lack of a deep understanding of the pathological mechanism of AS (6,7).

MicroRNAs (miRNAs) act as significant regulators in the pathophysiology of AS (8). As a member of miRNAs, the miR-106b family is associated with the level of genes regulating the cell cycle, which promotes cancer cell proliferation by shortening cell cycle progression (9). The differential expression of miR-106b has been proven to take part in the development of various diseases such as prostate cancer, lung cancer, and gastric cancer (10–12). A previous study shows that the abnormal expression of miR-106b is closely related with AS progression (13).

The biological function of miR-106b in disease can be via certain pathways (14). Yan et al. (15) showed that drugs could inhibit inflammation and promote the stability of AS plaques by regulating the PI3K/Akt pathway. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a viable target for the prevention of apoptosis in vascular endothelial cells (16,17). A previous study indicated that miR-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN (18). Shi et al. (19) reported that miR-106b-5p participates in the PI3K/AKT pathway by regulating PTEN, thereby promoting stem cell-like properties in liver cancer cells. Furthermore, human aortic endothelial cells (HAECs) are commonly used for the...
HAECs were seeded on a 96-well plate (1 and miR-106b mimics
ox-LDL group, miR-106b mimics
 treatment for 24 h. Then, all cells were divided into ox-LDL

Flow cytometry assay
Flow cytometry was used for HAEC apoptosis detection. Briefly, after re-suspended with 100 µL PBS, cells from each group were suspended with 5 µL FITC-AnnexinV (1 µg/mL) and 5 µL PI (1 µg/mL). Then, all cells were quantitatively detected by FACScan flow cytometry (BD Biosciences, USA) with CellQuest software (BD Biosciences).

TdT-mediated biotinylated nick end-labeling (TUNEL) assay
TUNEL assay was performed to detect the HAECs cell apoptosis from each group. According to the TUNEL kit (Beyotime Biotechnology, China) instructions, the HAECs were fixed with 4% formaldehyde and then permeated with 0.1% Triton X-100. Next, the cells were cultured with the mixture of TUNEL reaction at 37°C for 1 h. Finally, HAECs were observed under a laser confocal microscope (FV300, Olympus, Japan).
48 h, the dual luciferase reporter assay kit (Yuanping Hao Biotechnology Co., Ltd., China) was used for evaluation.

**Statistical analysis**

All data are reported as means ± SD. Comparisons between groups were performed with Student’s t-test (two groups) or one-way analysis of variance followed by Fisher’s LSD post hoc test (more than two groups). Statistical analysis was performed by Graphpad Prism 5 (Graphpad Software, USA). A P value less than 0.05 was considered to be significantly different.

**Results**

**MiR-106b was down-regulated in HAECs**

Compared with the control group, the expression of miR-106b in the ox-LDL group decreased significantly (P=0.014). Compared with the miR-106b NC + ox-LDL group, the expression of miR-106b in the mimics + ox-LDL group increased significantly (P<0.001, Figure 1).

**PTEN was the target gene of miR-106b**

The biological software Targetcsan predicted that the target gene of miR-106b was PTEN (Figure 2A). Moreover, the results of luciferase activity test showed that over-expression of miR-106b significantly decreased the luciferase activity of PTEN-WT-3’UTR, but did not inhibit the luciferase activity of PTEN-MUT-3’UTR (Figure 2B).

**MiR-106b inhibited the increase of PTEN in atherosclerosis**

The expression of PTEN mRNA and protein was detected by qRT-PCR (Figure 3A) and western blot (Figure 3B), respectively. The mRNA and protein levels of HAECs PTEN in the ox-LDL group were significantly higher than those in the control group (P<0.001). Meanwhile, the mRNA and protein levels of HAECs PTEN in the miR-106b mimics + ox-LDL group were significantly lower than those in the miR-106b NC + ox-LDL group (P<0.001). Moreover, the mRNA and protein levels of PTEN in the miR-106b mimics + PTEN + ox-LDL group were significantly higher than those in the miR-106b mimics + empty + ox-LDL group (P<0.001).

**Overexpression of miR-106b promoted proliferation and inhibited apoptosis of HAECs**

The proliferation of HAECs was detected by CCK-8 assay (Figure 4A). The activity of HAECs in the ox-LDL group was significantly lower than that in the control group (P<0.001). The activity of HAECs in the miR-106b mimics + ox-LDL group was significantly higher than that in the miR-106b NC + ox-LDL group (P<0.001). Meanwhile, the activity of HAECs in the miR-106b mimics + PTEN + ox-LDL group was significantly lower than that in the miR-106b mimics + empty + ox-LDL group (P<0.001).

To further investigate the relationship between HAECs activity and apoptosis, the DNA fragments were detected by TUNEL assay (Figure 4B). The number of TUNEL-positive cells in the ox-LDL group was significantly higher than that in the control group (P<0.001). Meanwhile, the number of TUNEL-positive cells in the miR-106b mimics + ox-LDL group was significantly lower than that in the miR-106b NC + ox-LDL group (P<0.001). Moreover, the number of TUNEL-positive cells in the miR-106b mimics + PTEN + ox-LDL group was significantly higher than that in the miR-106b + empty + ox-LDL group (P<0.001). Flow cytometry analysis showed that the apoptotic rate of HAECs in the ox-LDL group was significantly higher than that in the control group (P<0.001) (Figure 4C). The apoptotic rate of HAECs in the miR-106b mimics + ox-LDL group was significantly lower than that in the miR-106b NC + ox-LDL group (P<0.001). The apoptotic rate of HAECs in the miR-106b mimics + PTEN + ox-LDL group was significantly higher than that in the miR-106b mimics + empty + ox-LDL group (P<0.001). Western blot analysis showed that compared with the control group, the expressions of HAECs pro-apoptotic protein Bax, caspase-3, and caspase-9 in the ox-LDL group were significantly up-regulated (P<0.001), while the expressions of anti-apoptotic protein bcl-2 were significantly down-regulated (P<0.001) (Figure 4D). The expressions of HAECs pro-apoptotic protein Bax, caspase-3, and caspase-9 in the miR-106b mimics + ox-LDL group were significantly decreased (P<0.001), while the anti-apoptotic protein bcl-2 was significantly up-regulated (P<0.001). Furthermore, compared with miR-106b mimics + empty + ox-LDL group, Bax, caspase-3, and caspase-9 expression were significantly increased (P<0.001), and bcl-2 expression was significantly down-regulated (P<0.001) in the miR-106b mimics + PTEN + ox-LDL group. Taken together, these results suggested that overexpression of miR-106b in

---

**Figure 1.** Expression level of microRNA-106b in oxidized-low-density lipoproteins (ox-LDL)-induced human aortic endothelial cells. Data are reported as means ± SD. *P<0.05. **P<0.001 (ANOVA). NC: negative control.
ox-LDL-treated AS could promote HAECs proliferation and inhibit HAECs apoptosis.

MiR-106b targeted PTEN-activated PI3K/Akt signaling pathway in HAECs

Western blot assay showed that compared with the control group, p-P13K/PI3K and p-AKT/AKT expression in HAECs of the ox-LDL group were significantly down-regulated (P < 0.001). Moreover, compared with the miR-106b NC + ox-LDL group, the expressions of p-P13K/PI3K and p-AKT/AKT in the miR-106b mimics + PTEN + ox-LDL group were significantly up-regulated (P < 0.001).

Furthermore, compared with the miR-106b mimics + empty + ox-LDL group, the expressions of p-P13K/PI3K and p-AKT/AKT in the miR-106b mimics + PTEN + ox-LDL group were significantly down-regulated (P < 0.001) (Figure 5).

Discussion

AS is an important cause of death and morbidity worldwide (23,24). Although miRNAs participate in ox-LDL-induced apoptosis of vascular endothelial cells (25), the detailed mechanism of miR-106b in AS is still unclear.
In this study, ox-LDL-induced HAECs were used to simulate the pathological state of atherosclerotic endothelial cells. The results showed that miR-106b was down-expressed in AS endothelial cells, and overexpression of miR-106b promoted proliferation and inhibited apoptosis of AS endothelial cells. Importantly, miR-106b activated the PI3K/AKT pathway by down-regulating the level of PTEN.

Endothelial cell apoptosis is the first step in the pathogenesis of AS (26). As an anti-apoptotic modulator, the down-regulation of miR-106b can inhibit proliferation and migration of renal cancer cells and induce apoptosis (27,28). Li et al. (29) demonstrated that miR-106b-5p significantly enhances the expression level of Bcl-2 and reduces Bax expression. Importantly, members of the Bcl-2 gene family regulate programmed cell apoptosis by controlling intracellular signaling promoting apoptosis and anti-apoptosis (30). However, a previous study shows that overexpression of Bax accelerates apoptosis induced by cytokine deprivation in cell lines (31). Skala et al. (32) indicated that the high expression of pro-apoptotic Bax protein and low expression of anti-apoptotic Bcl-2 protein are beneficial to inhibit cell proliferation and promote apoptosis. More importantly, Bcl-2 protein also activates the downstream caspase cascade by regulating mitochondrial extracorporeal membrane permeabilization to perform apoptosis (33). Down-regulation of Bcl-2, procaspase-3, and pro-caspase-9 can accelerate the proliferation of HAECs and promote endothelial cell apoptosis, thereby promoting the formation of AS (34). In fact, miR-106a mediates the caspase-3 pathway (35). The apoptotic rate and caspase-3 activity are significantly increased when the expression of miR-106b is inhibited (35). miR-106b prevents the apoptosis of endothelial cells in AS by blocking the activation of caspase-3 (36). In this study, the expression of Bax, caspase-3, and caspase-9 in cells transfected with miR-106b was significantly increased.
decreased, while Bcl-2 was significantly up-regulated. Thus, we speculated that the overexpression of miR-106b in ox-LDL-induced AS inhibited endothelial cell apoptosis.

A previous study shows that the inhibition of miR-106b expression enhances the expression of PTEN (37). The up-regulation of PETN can induce endothelial cell dysfunction by attenuating the effectiveness and signaling of various angiogenic pathways in endothelial cells, which are involved in thrombosis of arteriovenous grafts (38). Moreover, overexpression of PTEN inhibits cell proliferation and increases the probability of apoptosis by inhibiting Bcl-2 and promoting caspase-3 (39). As the downstream of PTEN, p-Akt is positively regulated by the overexpression of miR-106b (40). A previous study indicates that the inhibition of miR-106b expression enhances PTEN level, but inhibits the activity of downstream PI3K/AKT pathway (37). Meanwhile, inhibition of the PTEN expression level in vascular endothelial cells by miR-106b-5p prevents apoptosis of endothelial cells in AS (36). In the current study, the Targetscan prediction and luciferase activity test showed that PTEN was a direct target of miR-106b. Meanwhile, western blot assay showed that overexpression of miR-106b inhibited endothelial cell apoptosis via the PTEN/P13K/AKT signaling pathway. Thus, we speculated that miR-106b might activate the PI3K/AKT pathway by down-regulating the expression of PTEN in ox-LDL induced HAECs.

In conclusion, overexpression of miR-106b in ox-LDL-induced AS inhibited endothelial cell apoptosis. Furthermore, miR-106b might activate the PI3K/AKT pathway by down-regulating the expression of PTEN in ox-LDL-induced HAECs. However, there are some limitations in this study including lack of clinical verification. Thus, future research is still needed.

References

1. Tabas I, Garcia-Cardeña G, Owens GK. The cell biology of disease: recent insights into the cellular biology of atherosclerosis. J Cell Biol 2015; 209: 13–22, doi: 10.1083/jcb.201412052.
2. Suciu CF, Prete M, Ruscitti P, Favoino E, Giacomelli R, Perosa F. Oxidized low density lipoproteins: the bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. Autoimmunity Rev 2018; 17: 366–375, doi: 10.1016/j.autrev.2017.11.028.
3. Sahebkar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant-antioxidant mechanisms. Natural Product Res 2015; 29: 491–492, doi: 10.1080/14786419.2014.956212.
4. Yuan J, Usman A, Das T, Patterson AJ, Gillard JH, Graves MJ. Imaging carotid atherosclerosis plaque ulceration: comparison of advanced imaging modalities and recent developments. AJNR Am J Neuroradiol 2017; 38: 664–671, doi: 10.3174/ajnr.A5026.
5. Rezvan A, Sur S, Jo H. Novel animal models of atherosclerosis. Biomed Engineering Lett 2015; 5: 181–187, doi: 10.1007/s13534-015-0200-4.
6. Micari A, Nerla R, Cremonesi A. Femoropopliteal atherosclerosis: do drug-eluting stents improve outcome? J Cardiovasc Med 2018; 19 Suppl 1: e91–e92, doi: 10.2459/JCM.0000000000000593.
7. Shan DK, Zhou Y, Wang YX, Gao X, Wang W, Yang JJ, et al. Population-based cohort study in outcome of phased progression of atherosclerosis in China (PERSUADE):
A study of miR-106b in atherosclerosis

7/8

objective, rationale and design. J Geriatric Cardiol 2017; 14: 491–495, doi: 10.11090/jissn.1671-5411.2017.08.001.

8. Feinberg MW, Moore KJ. MicroRNA regulation of atherosclerosis. Circ Res 2016; 118: 703–720, doi: 10.1161/CIRCRESAHA.115.306300.

9. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Miho K, Schelter JM, et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 2008; 28: 2167–2174, doi: 10.1128/MCB.01977-07.

10. Li B, Shi XB, Nori D, Chao CK, Chen AM, Valicenti R, et al. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 2011; 7: 567–574, doi: 10.1002/pros.21272.

11. Xue B, Lu QY, Massie L, Qualls C, Mao JT. Grape seed procyanidin extract against lung cancer: the role of microRNA-106b, bioavailability, and bioactivity. Oncotarget 2018; 9: 15579–15590, doi: 10.18632/oncotarget.24528.

12. Park SH, Lee J, Yeo JS. On-chip plasmonic detection of microRNA-106a in gastric cancer using hybridized gold nanoparticles. Sensors & Actuators B Chemical 2018; 262: 703–709, doi: 10.1016/j.snb.2018.02.010.

13. Ren J, Zhang J, Xu N, Han G, Geng Q, Song J, et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. Plos One 2013; 8: e80738, doi: 10.1371/journal.pone.0080738.

14. Chen S, Chen X, Xiu YL, Sun KX, Zhao Y. Inhibition of ovarian epithelial carcinoma tumorigenesis and progression by microRNA 106b mediated through the RhoC pathway. Plos One 2015; 10: e0125714, doi: 10.1371/journal.pone.0125714.

15. Yan H, Ma Y, Li Y, Zheng X, Lv P, Zhang Y, et al. Insulin inhibits inflammation and promotes atherosclerotic plaque stability via PI3K-Akt pathway activation. Immunol Lett 2016; 170: 7–14, doi: 10.1016/j.imlet.2015.12.003.

16. Koide M, Ikeda K, Akakabe Y, Kitamura Y, Ueyama T, et al. Apoptosis regulator through modulating IAP and BCL-2 family inhibitors. Mol Immunol 2018; 96108.

17. Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. Bcl-2 heterodimerizes from transformed and normal roots. J Biol Chem 2002; 277: 2901–2906, doi: 10.1016/j.jbc.2001.1419.

18. Liu Z, Yang D, Xie P, Ren G, Sun G, Zeng X, et al. Mir-106b and Mir-15b modulate apoptosis and angiogenesis in myocardial infarction. Cell Physiol Biochem 2012; 29: 851–862, doi: 10.1159/000258197.

19. Li Y, Chen D, Su Z, Liu J, Jin L, Shi M, et al. MicroRNA-106b functions as an oncogene in renal cell carcinoma by affecting cell proliferation, migration and apoptosis. Mol Med Rep 2016; 13: 1420–1426, doi: 10.3892/mmr.2015.4656.

20. Li P, Shen M, Gao F, Wu J, Zhang J, Teng F, et al. An antagonist to microRNA-106b-5p ameliorates cerebral ischemia and reperfusion injury in rats via inhibiting apoptosis and oxidative stress. Mol Neurobiol 2016; 54: 2901–2921, doi: 10.1007/s12035-016-9842-1.

21. Ashkenazi A, Fairbrother WJ, Levers JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 2017; 16: 273–284, doi: 10.1038/nrd.2016.253.

22. Oltvai ZN, Milliman L, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619, doi: 10.1016/0092-8674(93)90509-O.

23. Skala E, Sitarek P, Toma M, Szmajr J, Radek M, Nieborowska-Skorska M, et al. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots. J Pharm Pharmacol 2016; 68: 1454–1464, doi: 10.1111/jphp.12619.

24. Zheng JH, Viacava Follis A, Kriwacki RW, Moldoveanu T. Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J 2016; 283: 2690–2700, doi: 10.1111/febs.13527.

25. Li Y, Zhang K, Mao W. Inhibition of miR-34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis. Mol Med Rep 2018; 17: 4643–4650, doi: 10.3892/mmr.2018.8411.
35. Lu Z, Li S, Zhao S, Fa X. Upregulated miR-17 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation and apoptosis by targeting mitofusin 2. *Med Sci Monit* 2016; 22: 3301–3308, doi: 10.12659/MSM.900487.

36. Zhang J, Li SF, Chen H, Song JX. MiR-106b-5p inhibits tumor necrosis factor-α-induced apoptosis by targeting phosphatase and tensin homolog deleted on chromosome 10 in vascular endothelial cells. *Chin Med J* 2016; 129: 1406–1412, doi: 10.4103/0366-6999.183414.

37. Zheng Z, Zhang Y, Zhang Z, Yang Y, Song T. Effect of miR-106b on invasiveness of pituitary adenoma via PTEN-PI3K/AKT. *Med Sci Monit* 2017; 23: 1277–1285, doi: 10.12659/MSM.900092.

38. Kuo HM, Lin CY, Lam HC, Lin PR, Chan HH, Tseng JC, et al. PTEN overexpression attenuates angiogenic processes of endothelial cells by blockade of endothelin-1/endothelin B receptor signaling. *Atherosclerosis* 2012; 221: 341–349, doi: 10.1016/j.atherosclerosis.2010.08.067.

39. Cheng ZY, Liang WT, Niu ZY, Xue F, Yao L. Effects of wild type PTEN gene on proliferation, apoptosis and the influence on apoptosis key factor Bcl-2 and caspase family on K562 cells [in Chinese]. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2009; 7: 679–683.

40. Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y, Yuan L, et al. MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer. *J Transl Med* 2015; 13: 252, doi: 10.1186/s12967-015-0592-z.